Search
Strontium chloride
go.drugbank.com/drugs/DB13987ApprovedWithdrawnStrontium chloride (SrCl2) is a salt of strontium and chloride. SrCl2 is useful in reducing tooth sensitivity by forming a barrier over microscopic tubules in the dentin containing nerve endings that have become exposed by gum recession ...
AMB-301
go.drugbank.com/drugs/DB18094ExperimentalAMB-301 is an AAV gene therapy delivering E-selectin.[L48101] It is under investigation for the treatment of Buerger disease.
Levosalbutamol
go.drugbank.com/drugs/DB13139ApprovedThe enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol
Desflurane
go.drugbank.com/drugs/DB01189ApprovedInvestigationalDesflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as methoxyflurane, sevoflurane, enflurane, or isoflurane. . It was developed in the late 1980s out of ...
Zinc cation
go.drugbank.com/drugs/DB14532InvestigationalMixtures: Orajel 4X Medicated For Toothache and Gum, Orajel 3X Medicated For Toothache and GumDaxibotulinumtoxinA
go.drugbank.com/drugs/DB17929ApprovedInvestigationalDaxibotulinumtoxinA is an acetylcholine release inhibitor and neuromuscular blocking agent. … _C. botulinum_ is known to produce toxins that can cause botulism in humans.
Nusinersen
go.drugbank.com/drugs/DB13161ApprovedInvestigationalAn antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S.
Somapacitan
go.drugbank.com/drugs/DB15093ApprovedInvestigational[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily.
Categories: Sex Hormones and InsulinsMavacamten
go.drugbank.com/drugs/DB14921ApprovedInvestigationalMavacamten is a myosin inhibitor indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM). It received initial US FDA approval in 2022, and it is ...